Search Medical Condition
Please enter condition
Please choose location from dropdown

Bebington, United Kingdom Clinical Trials

A listing of Bebington, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (255) clinical trials

Open-Label Multi-Center Two-Part Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

This is a Phase 1, open-label, two-part study designed to characterize the PK of an IV dose of approximately 12 g tazemetostat that contains approximately 500 nCi of [14C] tazemetostat and the ADME of an oral dose of 800 mg tazemetostat that contains approximately 400 Ci of [14C]-labeled tazemetostat in ...

Phase

0.0 miles

Learn More »

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Subjects should continue on the treatment regimen that the subject was receiving in the prior study. Dose changes of any of the prior therapies subjects were receiving on the previous protocol are allowed after medical monitor approval. The day 1 visit for this study should coincide with the last treatment ...

Phase

0.0 miles

Learn More »

Ph II Cabazitaxel DD Liposarcoma

Soft tissue sarcomas (STS) are a rare group of malignant heterogenous tumors (> 50 histological subtypes, including liposarcoma, the commonest subtype of STS) with distinct genetic, pathological and clinical profiles, and varying patterns of tumor spread. The optimal cytotoxic treatment for this group of patients remains uncertain. Single agents which ...

Phase

0.0 miles

Learn More »

Study of Pembrolizumab (MK-3475) in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) (MK-3475-629/KEYNOTE-629)

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic cutaneous Squamous Cell Carcinoma (R/M cSCC) that is not amenable to surgery and/or radiation and/or systemic therapies.

Phase

0.0 miles

Learn More »

Ph II CABOGIST in GIST

The study is a multi-center, multi-national, open label, single arm Phase II study of single-agent cabozantinib. The objective of the study is to assess the safety and activity of cabozantinib in patients with metastatic GIST who have previously progressed on imatinib and sunitinib and have not been exposed yet to ...

Phase

0.0 miles

Learn More »

WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer

Patients with head and neck cancer with high-risk features are at increased risk of relapse after surgery. Surgery, often followed by cisplatin chemotherapy and radiotherapy is currently the standard treatment offered. Whilst chemo-radiotherapy improves cure rates, outcomes remain poor, and treatment has a significant impact on quality of life. Chemotherapy ...

Phase

1.62 miles

Learn More »

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment nave and to compare lorlatinib to crizotinib with respect to overall survival in the same population

Phase

1.62 miles

Learn More »

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

This Phase II study is designed to evaluate the safety and efficacy of IMCgp100 compared with Investigator's Choice (dacarbazine, ipilimumab or pembrolizumab) in HLA-A*0201 positive adult patients with advanced UM treated in the first line setting with no prior systemic or liver-directed chemo-, radio- or immune-therapy administered in the advanced ...

Phase

1.62 miles

Learn More »

Investigation of a Therapeutic Vaccine (ACIT-1) in Late Stage Cancer

The immune system has an important role in helping prevent cancer by destroying early cancer cells. When cancer does develop antigen-specific immune (T) cells are still present in the blood but are either not responding or are not effective. Vaccines stimulate these T cells to respond and kill cancer cells. ...

Phase

1.62 miles

Learn More »